A new guideline for cholesterol management was released by the American Heart Association and the American College of Cardiology on Apr. 6, coinciding with important findings from a major clinical trial that may influence future treatment strategies for patients at high risk of cardiovascular disease.
The timing highlights how quickly scientific evidence can advance compared to the development of official guidelines. This is especially relevant as results from the VESALIUS-CV trial emerged shortly after the finalization of the latest cholesterol recommendations, potentially impacting how doctors approach low-density lipoprotein cholesterol (LDL-C) targets in practice.
The VESALIUS-CV study included over 12,000 participants with elevated cardiovascular risk but no prior stroke or heart attack. These individuals were randomly assigned to receive evolocumab—a medication designed to lower LDL-C—on top of standard statin therapy or a placebo. Over an average follow-up period of nearly five years, those treated with evolocumab saw their LDL-C levels drop by more than half compared to placebo, reaching a median level of 45 mg/dL versus 109 mg/dL in the control group. The study reported significant reductions in major adverse cardiovascular events without increased safety risks between groups.
According to the new guidelines published in the Journal of the American College of Cardiology, screening for lipid disorders is recommended as early as age two for children with a family history or other risk factors and again at ages nine to eleven and nineteen for others. The guidelines set different LDL-C targets based on individual risk: less than 100 mg/dL for borderline or intermediate-risk patients starting statins; less than 70 mg/dL and less than 55 mg/dL are advised for those at high and very high risk respectively.
However, since data from VESALIUS-CV were not available during guideline review, experts now suggest that distinctions between various categories of cardiovascular disease risk may need reconsideration. They propose that future updates should include one care pathway aiming for an LDL-C goal below 55 mg/dL among all affected patients regardless of prior events like stroke or heart attack.
Looking ahead, authors note that further revisions will likely incorporate these new findings into broader recommendations—especially regarding intensive LDL-lowering treatments in people with diabetes or moderate subclinical atherosclerosis—to better address evolving evidence and patient needs.
